Sentinel lymph-node biopsy in patients with squamous cell carcinoma of the penis
Article first published online: 24 FEB 2009
© 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL
Volume 103, Issue 9, pages 1199–1203, May 2009
How to Cite
Jensen, J. B., Jensen, K. M.-E., Ulhøi, B. P., Nielsen, S. S. and Lundbeck, F. (2009), Sentinel lymph-node biopsy in patients with squamous cell carcinoma of the penis. BJU International, 103: 1199–1203. doi: 10.1111/j.1464-410X.2009.08449.x
- Issue published online: 7 APR 2009
- Article first published online: 24 FEB 2009
- Accepted for publication 5 September 2008
- false-negative rate;
- penile cancer;
- sentinel lymph-node biopsy
To evaluate a single-centre experience with sentinel lymph-node biopsy (SLNB) as a staging procedure in patients with squamous cell carcinoma (SCC) of the penis.
PATIENTS AND METHODS
The study included 60 patients with SCC of the penis, who had SLNB in all groins where no palpable nodes were found, and in groins with palpable nodes with negative fine-needle aspiration cytology. Lymphoscintigraphy and intraoperative lymph node detection was done using 99mTc-nanocolloid and no use of blue dye.
In all, there were 97 SLNB procedures in 52 patients; 20 (20.6%) of the SLNB were positive for nodal metastases. Two negative SLNB proved to be false-negative during the observation period. The false negative-rate was 9%, the sensitivity 91% and the negative predictive value 97.5%. Minor early complications occurred after 4% of the SLNB procedures. No major or late complications were recorded.
SLNB is minimally invasive and can be used as a safe and reliable staging procedure in patients with SCC of the penis. Thus standard lymph-node dissection can be avoided in most patients.